Skip to main content

Cancer

Cancer Research Institute

Clinical Trials

Showing 28-36 out of 125 results.
NCT04836390

A Phase II Pilot Study of Donor-Derived Ex-VivoExpanded Natural Killer Cell Infusions in Childrenand Young Adults with High-Risk Acute Myeloid Leukemia Receiving Myeloablative HLA Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study (EXCEL Trial) PTCTC CT2001.

Icon for trial | CT2001 A Phase II Pilot Study of Donor-Derived Ex-VivoExpanded Natural Killer Cell Infusions in Childrenand Young Adults with High-Risk Acute Myeloid Leukemia Receiving Myeloablative HLA Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatri

This study is currently enrolling.

Participants will be invited to join this study if they have a blood disease called acute myeloid leukemia (AML) and it has been decided that they need a transplant as part of their treatment plan. The purpose of this research ...

NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)

Icon for trial | CO44668 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)

This study is currently enrolling.

The purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this study, you will get either tir ...

NCT05281471

A Randomized Phase 3 Study Assessing the Efficacy and Safety
of Olvi-Vec followed by Platinum-doublet Chemotherapy and
Bevacizumab Compared with Platinum-doublet Chemotherapy and
Bevacizumab in Women with Platinum-Resistant/Refractory
Ovarian Cancer (OnPrime Study

Icon for trial | OLVI-VEC-022 A Randomized Phase 3 Study Assessing the Efficacy and Safety 
of Olvi-Vec followed by Platinum-doublet Chemotherapy and 
Bevacizumab Compared with Platinum-doublet Chemotherapy and 
Bevacizumab in Women with Platinum-Resistant/Refractory 
Ova

This study is currently enrolling.

You are invited to take part in a research study. This research study is studying Olvi-Vec as a possible treatment for platinum-resistant or platinum-refractory ovarian cancer including fallopian tube cancer and peritoneal carc ...

NCT04793958

A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Icon for trial | 849-010 A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

This study is currently enrolling.

This is a study involving an investigational (experimental) drug called MRTX849, being developed by Mirati Therapeutics, Inc., which is the company that provides MRTX849 study drug and is funding and organizing the study. Inves ...